Duaklir Pressair (aclidinium bromide and formoterol fumarate; Circassia) is now available for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Duaklir Pressair combines aclidinium bromide, a long-acting muscarinic antagonist (LAMA), and formoterol fumarate, a long-acting beta2-adrenergic agonist (LABA). The approval was supported by three phase 3 trials in which Duaklir Pressair demonstrated a statistically significant increase in mean change from baseline in trough forced expiratory volume in 1 second (FEV1) and change from baseline in 1-hour post-dose FEV1 at Week 24 relative to formoterol fumarate 12mcg and aclidinium 400mcg, respectively.
The active ingredients in Duaklir Pressair are administered using a multidose dry powder inhaler which delivers 60 metered doses or 30 metered doses. Each actuation provides a metered dose of 12mg of the formulation which contains lactose monohydrate (may contain milk proteins; treatment in patients with severe hypersensitivity is contraindicated) as the carrier, 400mcg of aclidinium bromide (equivalent to 343mcg of aclidinium), and 12mcg of formoterol fumarate (as a dihydrate, equivalent to 11.5mcg of formoterol fumarate anhydrous and 9.8mcg of formoterol).
The inhaler is comprised of an assembled plastic dosing mechanism with a dose indicator, a drug-product storage unit containing the drug-product formulation, and a mouthpiece covered by a protective cap; it should be stored in a sealed bag and only opened immediately before use. The Pressair inhaler should be thrown away after the marking “0” with a red background shows in the middle of the dose indicator, when the device is empty and locks out, or 2 months after the date the sealed bag was opened, whichever comes first.
Duaklir Pressair is not meant to relieve acute symptoms of COPD and extra doses should not be used for that purpose.
For more information visit duaklir.com.
This article originally appeared on MPR